Georgia Nelson Utilising BTL’s coveted technology, the Emface offers an innovative non-invasive facial treatment set to revolutionise the industry.
The past year has been huge for BTL Aesthetics, celebrating one million treatments of its Emsculpt and Emsculpt NEO devices and accelerated adoption of the Emsella device. The Emsculpt NEO continues to revolutionise the non-invasive body sculpting market by providing the ultimate combination of fat reduction and muscle building. Meanwhile, the Emsella has become a leading treatment option for all forms of urinary incontinence and women’s wellness.
And the leading aesthetics device company isn’t slowing down in 2022.
BTL’s latest device Emface is set to disrupt the aesthetics market yet again, offering a non-invasive solution to facial injectables and other tweakments.
“This device presents a paradigm shift in facial treatments. Emface will do for the face what Emsculpt did for the body.”
— Dr Yael Halaas, leading New York-based plastic surgeon.
The Emface utilises a patented technology of muscle contraction and skin tissue heating, and is the result of combining many years of institutional knowledge of the simultaneous emission of radio frequency and BTL’s high-intensity focused electromagnetic (HIFEM™) technology.
“We are thrilled to enter the facial aesthetics market with this breakthrough technology, with launch plans for later this year,” added Ron Borsheim, VP of Business Development.
Stay tuned for more updates and when you can expect Emface to launch in Australia!
DID YOU KNOW:
There are 5 ways you can catch up with SPA+CLINIC?
- Our quarterly print magazine, delivered to your door. Subscribe here.
- Our website, which is updated daily with its own completely unique content and breaking news.
- Our weekly newsletter – free to your inbox! Subscribe here.
- Our digital magazine – click here to view previous issues.
- Our social media – see daily updates on our Instagram, Facebook & Linkedin
